Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 80425-0363

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 80425-0363). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 1 (Rabeprazole Sodium Dr 20mg 80425 0363 01)

RABEPRAZOLE SODIUM DR 20MG TABLET, DELAYED RELEASE oral tablets for human prescription by Advanced Rx of Tennessee, LLC. The label shows a quantity of 30 tablets, with storage instructions of 20°-25°C (68°-77°F). It includes a comparison to ACIPHEX and lists expiration date as 3/31/2026. The label also contains NDC codes, lot number placeholder, and a QR code.*

FDA Label Image

Label 2 (Rabeprazole Sodium Dr 20mg 80425 0363 02)

RABEPRAZOLE SODIUM DR 20MG TABLET carton label showing the product name, strength, and dosage form. The label includes manufacturer information for Advanced Rx of Tennessee, LLC, a barcode, and storage instructions at 20°-25°C. It also references comparison to ACIPHEX and lists a NDC number with expiration date 3/31/2026.*

FDA Label Image

Label 3 (Rabeprazole Sodium Dr 20mg 80425 0363 03)

Label for Rabeprazole Sodium 20 mg delayed release tablets by Advanced Rx of Tennessee, LLC. It includes storage instructions (20°-25°C), prescription-only status, NDC 80425-0363, and expiration date 3/31/2026. The label also references comparison to ACIPHEX with associated source NDC and lot information.*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure diagram of rabeprazole sodium, the active ingredient in RABEPRAZOLE SODIUM delayed-release oral tablets 20 mg, illustrating the molecular connectivity and arrangement of atoms.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph comparing mean heartburn scores over a 28-day study period among three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis represents study days before and after day 0, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe).*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph depicting mean heartburn scores over study days for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis shows days relative to treatment start (day 0), and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph illustrates a decline in heartburn scores following the start of treatment.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing heartburn scores over time between placebo and rabeprazole sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph illustrates the decrease in heartburn severity with rabeprazole treatment compared to placebo over the study period.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: placebo (n=58) and Rabeprazole sodium 20 mg (n=59). The x-axis shows study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 to 4, with 0 indicating no heartburn and 4 indicating very severe heartburn. The graph illustrates a decline in heartburn severity over time for both groups, with the Rabeprazole sodium group showing consistently lower scores.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.